Ali Ataya, MD - Research

Research at a glance

Top areas of exploration

Dyspnea , 14 publications
Hypertension, Pulmonary , 6 publications
Pulmonary Alveolar Proteinosis , 5 publications
Lung , 5 publications

Research activity

116 publications

405 citations

Why is this important?

Active clinical trials

IMPALA-2

160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for 48 weeks. Subjects completing the 48 week placebo-controlled period will receive鈥�

Investigator: Ali Ataya
Status: Accepting Candidates
Ages: 18 Years - N/A
Sexes: All

ROR-PH-303 (APD811-303)

Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.

Investigator: Ali Ataya
Status: Accepting Candidates
Ages: 18 Years - N/A
Sexes: All

United therapeutics 301

Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World Health Organization (WHO)鈥�

Investigator: Ali Ataya
Status: Accepting Candidates
Ages: 18 Years - N/A
Sexes: All

My publications

116 publications

2025

A patient journey map for people living with autoimmune pulmonary alveolar proteinosis

Respiratory Medicine

2025

Development of New Intrapulmonary Shunts in Pulmonary Arterial Hypertension Treated with Sotatercept

American Journal of Respiratory and Critical Care Medicine

2025

Glycogen storage disease type V: delayed diagnosis of a cause of exercise intolerance in a patient with hereditary haemorrhagic telangiectasia.

BMJ case reports

鈥�

2025

The healthcare burden of pulmonary alveolar proteinosis (PAP).

Orphanet journal of rare diseases

鈥�

2024

A 35-Year-Old Woman With Placenta Previa and Postpartum Cardiovascular Collapse.

Chest

鈥�

BOB体育